Impact du probiotique Streptococcus Salivarius M18 sur la microbiote orale et le contrôle glycémique chez les patients atteints de diabète de type 2

This study focuses on the impact of a specific probiotic, Streptococcus Salivarius M18 strain (Dentoblis™), on the oral health and blood sugar control of individuals with type 2 diabetes. The research aims to understand how this probiotic affects the balance of bacteria in the mouth and certain diabetes-related markers, like fructosamine and C-reactive protein (CRP). The study involves individuals aged 30 to 65 who have both type 2 diabetes and periodontitis, a common gum disease. The goal is to explore if this probiotic can improve oral health and diabetes management, addressing a potential gap in care for those with these conditions. During the study, participants are randomly assigned to either a probiotic or a placebo group. The probiotic is given orally and contains 4 billion colony forming units (CFU/g) of the Streptococcus Salivarius M18 strain. Over a 30-day period, changes in the quantity of oral bacteria and diabetes-related markers are measured and compared. The primary outcomes include changes in blood fructosamine levels and shifts in the colony counts of specific oral bacteria. These measurements help researchers understand the potential benefits and risks of using this probiotic for managing type 2 diabetes and periodontitis.